{"id":"W3044651017","doi":"10.1016/s0140-6736(20)30732-7","title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":491,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Innovaderm (Canada)","funders":"LEO Pharma; Galderma; Lundbeckfonden; Glenmark Pharmaceuticals; Kiniksa Pharmaceuticals; British Skin Foundation; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Sanofi; Pfizer; Eli Lilly and Company","keywords":"Eczema Area and Severity Index; Medicine; Atopic dermatitis; Placebo; Adverse effect; Randomized controlled trial; Internal medicine; Clinical trial; Janus kinase inhibitor; Clinical endpoint; Severity of illness; Physical therapy; Pediatrics; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001751599,0.001516478,0.00338086,0.0003252274,0.0004359704,0.001152516,0.0009087255,0.002467005,0.006021852],"category_scores_gemma":[0.001673874,0.0006504593,0.002422063,0.0003072222,0.0009308024,0.001250056,0.0003489336,0.00360306,0.0009446568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005703336,"about_ca_system_score_gemma":0.0006190529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007285856,"about_ca_topic_score_gemma":0.002026591,"domain_scores_codex":[0.9994506,0.0002548436,0.00004096627,0.0001113316,0.0000468357,0.00009544446],"domain_scores_gemma":[0.9992355,0.0002320741,0.0001833796,0.0000459719,0.00004703091,0.0002560669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.974237,0.002915493,0.0008877005,0.001300407,0.001598984,0.00007027558,0.00007685283,0.000166389,0.002818312,0.0001016024,0.001058144,0.01476894],"study_design_scores_gemma":[0.9597842,0.03542816,0.003070678,0.00005992591,0.0006154721,0.00006268868,0.00002570533,0.0001293359,0.0001727278,0.00008463483,0.0005544515,0.00001201047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.970749,0.02192626,0.0004255996,0.0009147619,0.0006829667,0.001803534,0.0009589306,0.0001052825,0.002433654],"genre_scores_gemma":[0.9854051,0.006367631,0.0008509763,0.001789828,0.0005026907,0.001744248,0.0009632094,0.00002146364,0.002354899],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006021852,"threshold_uncertainty_score":0.02014512,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02407745882816653,"score_gpt":0.2923664040459151,"score_spread":0.2682889452177485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}